Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19

Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19

WESTMINSTER -- Reven Holdings, Inc. today announced the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients ( ClinicalTrials.gov Identifier: NCT04708340; ... Read More

Thursday April 29, 2021 0 comments Tags: Westminster, Reven Holdings, COVID-19, Fatih Uckun, Peter Lange, Michael Volk, Brian Denomme

Reven Pharmaceuticals reports positive results regarding clinical safety and preclinical efficacy of Its COVID-19 drug candidate Rejuveinix

Reven Pharmaceuticals reports positive results regarding clinical safety and preclinical efficacy of Its COVID-19 drug candidate Rejuveinix

GOLDEN -- Reven Holdings, Inc. today announced publication of a peer-reviewed article in the prestigious medical journal, Frontiers in Pharmacology, Section: Respiratory Pharmacology. In the... Read More

Thursday November 12, 2020 0 comments Tags: Golden, Reven Holdings, Reven Pharmaceuticals, COVID-19, Rejuveinix, Fatih Uckun, Peter Lange, Brian Denomme

Reven Pharmaceuticals wins FDA nod of IND application for COVID treatment with Rejuveinix

Reven Pharmaceuticals wins FDA nod of IND application for COVID treatment with Rejuveinix

GOLDEN -- Reven today announced the U.S. Food and Drug Administration has approved its Investigational New Drug application in connection with its lead anti-inflammatory/anti-oxidant... Read More

Thursday October 22, 2020 0 comments Tags: Golden, Reven Pharmaceuticals, Reven Holdings, Rejuveinix, COVID-19, Fatih Uckun, Michael Volk, Peter Lange